Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.36 |
| ▸ | OGA | O60502 | 8/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.32 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.32 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | GRM5 | P41594 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | PGK1 | P00558 | 1/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4250899 | 0.83 | ATR (0.37) | TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL4256289 | 0.75 | PGK1 (0.35) | SMN1; SMN2GRM5LMNAPKMPGK1 | |
| SCHEMBL22262594 | 0.74 | PGK1 (0.37) | EGLN1SMN1; SMN2GRM5LMNAPKM | |
| SCHEMBL22262593 | 0.74 | PGK1 (0.37) | EGLN1SMN1; SMN2GRM5LMNAPKM | |
| SCHEMBL21052161 | 0.70 | NPC1 (0.44) | LMNAFFAR1FFAR4 | |
| SCHEMBL20397416 | 0.69 | KCNQ3 (0.37) | SMN1; SMN2CYP1A2 | |
| SCHEMBL16702509 | 0.69 | ABL1 (0.38) | SMN1; SMN2 | |
| SCHEMBL3708385 | 0.67 | KCNQ3 (0.33) | SMN1; SMN2 | |
| SCHEMBL31125285 | 0.67 | EGLN1 (0.38) | EGLN1OGAPGK1 | |
| SCHEMBL16702016 | 0.67 | FFAR2 (0.34) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2826778-B1 | Azaindole derivatives as CFTR modulators | VERTEX PHARMA (US) | 2017-09-20 | — | — | EP | disclosed |
| US-9732080-B2 | Azaindole derivatives as CFTR modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-08-15 | — | — | US | disclosed |
| US-20150336956-A1 | AZAINDOLE DERIVATIVES AS CFTR MODULATORS | VERTEX PHARAMCEUTICALS INCORPORATED | 2015-11-26 | — | — | US | disclosed |
| US-9102672-B2 | Azaindole derivatives as CFTR modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-08-11 | — | — | US | disclosed |
| EP-2826778-A1 | Azaindole derivatives as CFTR modulators | Vertex Pharmaceuticals Incorporated (US) | 2015-01-21 | — | — | EP | disclosed |
| EP-2118103-B1 | AZAINDOLE DERIVATIVES AS CFTR MODULATORS | VERTEX PHARMA (US) | 2014-04-23 | — | — | EP | disclosed |
| US-20140024672-A1 | AZAINDOLE DERIVATIVES AS CFTR MODULATORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-01-23 | — | — | US | disclosed |
| US-8563573-B2 | Azaindole derivatives as CFTR modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-10-22 | — | — | US | disclosed |
| EP-2118103-A2 | AZAINDOLE DERIVATIVES AS CFTR MODULATORS | Vertex Pharmaceuticals Incorporated (US) | 2009-11-18 | — | — | EP | disclosed |
| US-20090253736-A1 | AZAINDOLE DERIVATIVES AS CFTR MODULATORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-10-08 | — | — | US | disclosed |
| WO-2008127399-A2 | AZAINDOLE DERIVATIVES AS CFTR MODULATORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140024672-A1 | AZAINDOLE DERIVATIVES AS CFTR MODULATORS | CFTR, ABCB1, ABCC2 | EGLN1 3514/4885OGA 2756/4885HIF1A 3899/4885 |
| US-20150336956-A1 | AZAINDOLE DERIVATIVES AS CFTR MODULATORS | CFTR, ABCB1, ABCC2 | EGLN1 3514/4885OGA 2756/4885HIF1A 3899/4885 |
| US-20090253736-A1 | AZAINDOLE DERIVATIVES AS CFTR MODULATORS | CFTR, ABCB1, ABCC2 | EGLN1 3514/4885OGA 2756/4885HIF1A 3899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.